a public good project by the
Synthesis
Company
of California

© 2026

Nicolas Willand | doi.page

0 works0 citations0 h-index

Nicolas Willand

Inserm(FR)Université de Lille(FR)Institut Pasteur de Lille(FR)

Publications by Year

Research Areas

Tuberculosis Research and Epidemiology, Cancer therapeutics and mechanisms, Biochemical and Molecular Research, Chemical Synthesis and Analysis, Antibiotic Resistance in Bacteria

Most-Cited Works

→ Tuberculosis: The drug development pipeline at a glance(2012)172 cited
→ Synthetic EthR inhibitors boost antituberculous activity of ethionamide(2009)172 cited
→ Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420(2017)141 cited
→ Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles(2017)96 cited
→ Natural Compounds: Leads or Ideas? Bioinspired Molecules for Drug Discovery(2008)88 cited
→ Ethionamide Boosters: Synthesis, Biological Activity, and Structure−Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors(2011)84 cited
→

Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors

(2011)

70 cited

→ Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis(2019)67 cited

→ Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches(2014)64 cited

→ Exploring Drug Target Flexibility Using in Situ Click Chemistry: Application to a Mycobacterial Transcriptional Regulator(2010)63 cited